Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | NTRK2 fusion |
| Gene Variant Detail | |
| Relevant Treatment Approaches | Trk Receptor Inhibitor (Pan) |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04484142 | Phase II | Datopotamab deruxtecan | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | Completed | USA | NLD | ITA | HUN | FRA | ESP | DEU | 3 |
| NCT03520686 | Phase III | Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Ipilimumab + Nivolumab + Nogapendekin alfa inbakicept Carboplatin + Ipilimumab + Nab-paclitaxel + Nivolumab + Nogapendekin alfa inbakicept Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium Nogapendekin alfa inbakicept + Pembrolizumab Atezolizumab + Carboplatin + Nab-paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | Terminated | USA | 0 |
| NCT03215511 | Phase Ib/II | Selitrectinib | A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer | Completed | USA | ITA | IRL | FRA | ESP | DNK | DEU | BEL | AUS | 1 |
| NCT03994796 | Phase II | Adagrasib Abemaciclib GDC-0084 Entrectinib | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | Active, not recruiting | USA | 0 |
| NCT07355205 | Phase Ib/II | Ipilimumab + Nivolumab + Nogapendekin alfa inbakicept | First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN) | Recruiting | USA | 0 |
| NCT07020065 | Phase II | Carboplatin + Cemiplimab + Gemcitabine Carboplatin + Cemiplimab + Pemetrexed Disodium Cemiplimab Carboplatin + Cemiplimab + Paclitaxel | Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% | Recruiting | CHE | 0 |
| NCT04901806 | Phase Ib/II | PBI-200 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | DNK | DEU | AUS | 3 |
| NCT07217301 | Phase III | IBI363 Docetaxel | A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer (MarsLight-11) | Recruiting | USA | 2 |
| NCT04581824 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | ROU | POL | ITA | FRA | ESP | DEU | BRA | ARG | 3 |
| NCT06495125 | Phase II | Defactinib + Nivolumab + RO5126766 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT04923126 | Phase Ib/II | Mirdametinib | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | Recruiting | USA | 0 |
| NCT04467801 | Phase II | Ipatasertib Docetaxel + Ipatasertib | Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung) | Unknown status | USA | 0 |
| NCT05469178 | Phase Ib/II | Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Clinical Study of Bemcentinib with Standard of Care Chemoimmunotherapy in Untreated Advanced/metastatic Non-small Cell Lung Cancer Patients with a Mutation in the STK11 Gene | Terminated | USA | POL | ITA | HUN | GRC | FRA | ESP | 0 |
| NCT05153408 | Phase Ib/II | BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Terminated | USA | 0 |
| NCT03827850 | Phase II | Erdafitinib | FGFR Inhibitor in FGFR Dysregulated Cancer (FIND) | Terminated | DEU | 0 |
| NCT02097810 | Phase I | Entrectinib | Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1) | Completed | USA | 1 |
| NCT07566052 | Phase III | ASP3082 Docetaxel | A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation | Recruiting | USA | 1 |
| NCT05671510 | Phase III | ONC-392 Docetaxel | ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) | Recruiting | USA | TUR | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 2 |
| NCT05785754 | Phase I | Doxorubicin + Tebentafusp DCSZ11 + Pembrolizumab DCSZ11 | DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
| NCT04589845 | Phase II | Alectinib Divarasib Entrectinib | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Active, not recruiting | USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUS | 8 |
| NCT03155620 | Phase II | Tazemetostat Larotrectinib Vemurafenib Ivosidenib Palbociclib Selumetinib Tipifarnib LY3023414 Selpercatinib Olaparib Ulixertinib Erdafitinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Active, not recruiting | USA | CAN | AUS | 1 |
| NCT03953235 | Phase Ib/II | GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Completed | USA | 0 |
| NCT04655404 | Phase I | Larotrectinib | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion | Recruiting | USA | NZL | DEU | CAN | AUS | 0 |
| NCT06307795 | Phase I | ANS014004 | A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 1 |
| NCT05676749 | Phase I | Aldesleukin + C-TIL051 + Pembrolizumab | C-TIL051 in Non-Small Cell Lung Cancer | Terminated | USA | 0 |
| NCT05783323 | Phase II | Larotrectinib | Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer | Recruiting | USA | 0 |
| NCT04270591 | Phase Ib/II | SCC244 | Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | Recruiting | USA | 2 |
| NCT07227298 | Phase Ib/II | SSGJ-707 SGN-B6A + SSGJ-707 | Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | Recruiting | USA | ITA | FRA | ESP | DEU | 4 |
| NCT04265534 | Phase II | Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE) | Terminated | USA | 0 |
| NCT03213704 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
| NCT05935774 | Phase II | Atezolizumab + Trabedersen | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
| NCT04526691 | Phase I | Cisplatin + Datopotamab deruxtecan + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab deruxtecan + Pembrolizumab | Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | Active, not recruiting | USA | ITA | ESP | 2 |
| NCT05435846 | Phase I | Capmatinib + Trametinib | Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation | Terminated | USA | 0 |
| NCT06094296 | Phase II | Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | AUS | 0 |
| NCT05379595 | Phase Ib/II | Amivantamab-vmjw Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin | A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1) | Recruiting | USA | ITA | ESP | DEU | CAN | BEL | 5 |
| NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Completed | USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
| NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | NOR | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
| NCT02122913 | Phase I | Larotrectinib | A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer | Completed | USA | 0 |
| NCT02637687 | Phase I | Larotrectinib | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT) | Active, not recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | AUS | 4 |
| NCT01639508 | Phase II | Cabozantinib | Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | Recruiting | USA | 0 |
| NCT06532032 | Phase Ib/II | Amivantamab-vmjw + Docetaxel | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail) | Completed | USA | TUR | GBR | 1 |
| NCT07017829 | Phase II | GT103 + Pembrolizumab | GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT05313009 | Phase Ib/II | Sotorasib + TH-4000 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | Terminated | USA | 0 |
| NCT06528691 | Phase II | Entrectinib Carboplatin + Cyclophosphamide + Etoposide + Filgrastim Carboplatin + Cyclophosphamide + Etoposide + Pegfilgrastim | Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors | Recruiting | USA | BRA | 2 |
| NCT02587650 | Phase II | Ceritinib Capmatinib Regorafenib Entrectinib | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | Terminated | USA | 0 |
| NCT05241873 | Phase Ib/II | BLU-451 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Terminated | USA | CAN | 3 |
| NCT05064280 | Phase II | Lenvatinib + Pembrolizumab | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Recruiting | USA | 0 |
| NCT02650401 | Phase I | Entrectinib | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 2 |
| NCT04085315 | Phase I | Alisertib + Osimertinib | Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer | Recruiting | USA | 0 |
| NCT06364917 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | Recruiting | USA | 0 |
| NCT01804530 | Phase I | PLX7486 Gemcitabine + Nab-paclitaxel | Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT07227025 | Phase Ib/II | Amivantamab-vmjw + LY3537982 | A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer (KaRAnaSa) | Recruiting | USA | TUR | CAN | 2 |
| NCT03066661 | Expanded access | Entrectinib | Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions | No longer available | USA | 0 |
| NCT04827576 | Phase II | Docetaxel + Magrolimab | Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) | Terminated | USA | POL | GBR | FRA | ESP | 0 |
| NCT05886920 | Phase Ib/II | D3S-001 + D3S-002 D3S-002 | A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations | Recruiting | USA | AUS | 2 |
| NCT06946797 | Phase II | Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Ipilimumab + Nivolumab | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (CheckMate-1533) | Active, not recruiting | USA | ROU | POL | ITA | GRC | FRA | BRA | 2 |
| NCT07222566 | Phase III | SSGJ-707 Pembrolizumab | Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GRC | FRA | ESP | DEU | CZE | CAN | BRA | AUS | ARG | 5 |
| NCT06644768 | Phase Ib/II | Pembrolizumab DS-3201b + Pembrolizumab | A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Recruiting | USA | BRA | ARG | 3 |
| NCT05781308 | Phase II | Atezolizumab + Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE) | Active, not recruiting | FRA | 0 |
| NCT03834961 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | Active, not recruiting | USA | CAN | 0 |
| NCT05589818 | Phase II | Pembrolizumab | Pembrolizumab for Advanced NSCLC and PS 2-3 | Recruiting | USA | 0 |
| NCT05159245 | Phase II | Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE) | Recruiting | FIN | 0 |
| NCT06216301 | Phase III | Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2) | Recruiting | USA | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT | 2 |
| NCT06822543 | Phase II | Carboplatin + Datopotamab deruxtecan + Pembrolizumab | A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) (TROPICAL-1) | Recruiting | BRA | 0 |
| NCT05117242 | Phase II | Acasunlimab + Pembrolizumab Acasunlimab | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | 1 |
| NCT06625775 | Phase I | BBO-10203 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin BBO-10203 + Trastuzumab BBO-10203 + Fulvestrant + Ribociclib BBO-10203 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | BRA | AUS | 0 |
| NCT02465060 | Phase II | Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Active, not recruiting | USA | 2 |
| NCT05077800 | Phase II | Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin | FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer | Active, not recruiting | USA | 0 |
| NCT05541822 | Phase II | ABN401 + Lazertinib ABN401 | To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | Recruiting | USA | 2 |
| NCT03639714 | Phase Ib/II | GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab | A Study of a Personalized Neoantigen Cancer Vaccine | Completed | USA | AUS | 0 |
| NCT06074588 | Phase III | Docetaxel Sacituzumab tirumotecan Pemetrexed Disodium | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Active, not recruiting | USA | TUR | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 11 |
| NCT05215340 | Phase III | Pembrolizumab Datopotamab deruxtecan + Pembrolizumab | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
| NCT05200481 | Phase II | Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib | Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) (MP-ALK) | Active, not recruiting | FRA | 0 |
| NCT04862780 | Phase Ib/II | BLU-945 BLU-945 + Osimertinib | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Terminated | USA | NLD | GBR | FRA | ESP | CAN | 4 |
| NCT07405190 | Phase II | Ivonescimab Carboplatin + Ivonescimab + Pemetrexed Disodium | Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC | Not yet recruiting | USA | 0 |
| NCT05597800 | Phase II | Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Paclitaxel | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR) | Not yet recruiting | ITA | 0 |
| NCT04083976 | Phase II | Erdafitinib | A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR) | Completed | USA | POL | ITA | GBR | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 4 |
| NCT06758401 | Phase III | Pembrolizumab Pembrolizumab + SGN-B6A | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (Be6A Lung-02) | Recruiting | USA | TUR | SVK | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 7 |
| NCT06561386 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093) | Recruiting | USA | TUR | ROU | POL | NZL | NLD | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
| NCT04211337 | Phase III | Vandetanib Cabozantinib Selpercatinib | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) | Active, not recruiting | USA | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | 5 |
| NCT04094610 | Phase Ib/II | Repotrectinib | A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CAN | AUS | 3 |